{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:51:46Z","timestamp":1774579906534,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"crossref","award":["283955"],"award-info":[{"award-number":["283955"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12916-018-1094-7","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T10:08:44Z","timestamp":1531303724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2221-8898","authenticated-orcid":false,"given":"Alessia","family":"Melegaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Marziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Del Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Merler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"1094_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S0950268808000678","volume":"137","author":"A Gauthier","year":"2008","unstructured":"Gauthier A, Breuer J, Carrington D, Martin M, R\u00e9my V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2008;137:38\u201347.","journal-title":"Epidemiol Infect"},{"key":"1094_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1471-2334-10-230","volume":"10","author":"LE Gialloreti","year":"2010","unstructured":"Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230\u201311.","journal-title":"BMC Infect Dis"},{"key":"1094_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.vaccine.2012.05.050","volume":"31","author":"GS Goldman","year":"2013","unstructured":"Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine. 2013;31:1680\u201394.","journal-title":"Vaccine"},{"key":"1094_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4161\/hv.34311","volume":"11","author":"A Bechini","year":"2015","unstructured":"Bechini A, Boccalini S, Baldo V, Castiglia P, Gallo T, Giuffrida S, et al. Impact of universal vaccination against varicella in Italy. Hum Vaccin Immunother. 2015;11:63\u201371.","journal-title":"Hum Vaccin Immunother"},{"key":"1094_CR5","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1016\/j.vaccine.2017.06.011","volume":"35","author":"C Signorelli","year":"2017","unstructured":"Signorelli C, Guerra R, Siliquini R, Ricciardi W. Italy\u2019s response to vaccine hesitancy: an innovative and cost effective National Immunization Plan based on scientific evidence. Vaccine. 2017;35:4057\u20139.","journal-title":"Vaccine"},{"key":"1094_CR6","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1002\/jmv.10317","volume":"70","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70:S31\u20137.","journal-title":"J Med Virol"},{"key":"1094_CR7","first-page":"9","volume":"58","author":"RE Hope-Simpson","year":"1965","unstructured":"Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9\u201320.","journal-title":"Proc R Soc Med"},{"key":"1094_CR8","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1086\/430325","volume":"191","author":"AO Jumaan","year":"2005","unstructured":"Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992\u20132002. J Infect Dis. 2005;191:2002\u20137.","journal-title":"J Infect Dis"},{"key":"1094_CR9","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1086\/522162","volume":"197","author":"MA Reynolds","year":"2008","unstructured":"Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008;197:S224\u20137.","journal-title":"J Infect Dis"},{"key":"1094_CR10","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.","journal-title":"BMJ Open"},{"key":"1094_CR11","doi-asserted-by":"publisher","first-page":"20142509","DOI":"10.1098\/rspb.2014.2509","volume":"282","author":"V Marziano","year":"2015","unstructured":"Marziano V, Poletti P, Guzzetta G, Ajelli M, Manfredi P, Merler S. The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study. Proc R Soc B. 2015;282:20142509.","journal-title":"Proc R Soc B"},{"key":"1094_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jama.296.2.157","volume":"296","author":"M Mitka","year":"2006","unstructured":"Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. J Am Med Assoc. 2006;296:157\u20138.","journal-title":"J Am Med Assoc"},{"key":"1094_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2009","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2009;352:2271\u201384.","journal-title":"N Engl J Med"},{"key":"1094_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1017\/S0950268809990768","volume":"138","author":"M Karhunen","year":"2010","unstructured":"Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect. 2010;138:469\u201381.","journal-title":"Epidemiol Infect"},{"key":"1094_CR15","doi-asserted-by":"publisher","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","volume":"8","author":"P Poletti","year":"2013","unstructured":"Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One. 2013;8:e60732.","journal-title":"PLoS One"},{"key":"1094_CR16","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","volume":"28","author":"M Brisson","year":"2010","unstructured":"Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine. 2010;28:3385\u201397.","journal-title":"Vaccine"},{"key":"1094_CR17","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","volume":"29","author":"AJ van Hoek","year":"2011","unstructured":"van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay NJ. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine. 2011;29:2411\u201320.","journal-title":"Vaccine"},{"key":"1094_CR18","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/aje\/kws370","volume":"177","author":"G Guzzetta","year":"2013","unstructured":"Guzzetta G, Poletti P, Del Fava E, Ajelli M, Scalia Tomba G, Merler S, et al. Hope-Simpson's progressive immunity hypothesis as a possible explanation for herpes zoster incidence data. Am J Epidemiol. 2013;177:1134\u201342.","journal-title":"Am J Epidemiol"},{"key":"1094_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/aje\/kwv240","volume":"183","author":"G Guzzetta","year":"2016","unstructured":"Guzzetta G, Poletti P, Merler S, Manfredi P. The epidemiology of herpes zoster after varicella immunization under different biological hypotheses: perspectives from mathematical modeling. Am J Epidemiol. 2016;183:765\u201373.","journal-title":"Am J Epidemiol"},{"key":"1094_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/00365549309008578","volume":"25","author":"K Terada","year":"2009","unstructured":"Terada K, Kawano S, Yoshihiro K, Morita T. Proliferative response to varicella-zoster virus is inversely related to development of high levels of varicella-zoster virus specific IgG antibodies. Scand J Infect Dis. 2009;25:775\u20138.","journal-title":"Scand J Infect Dis"},{"key":"1094_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1086\/421277","volume":"190","author":"MTM Vossen","year":"2004","unstructured":"Vossen MTM, Gent M-R, Weel JFL, de Jong MD, van Lier RAW, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis. 2004;190:72\u201382.","journal-title":"J Infect Dis"},{"key":"1094_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/vim.2010.0031","volume":"24","author":"B Ogunjimi","year":"2011","unstructured":"Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, Ieven M, et al. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunol. 2011;24:151\u20137.","journal-title":"Viral Immunol"},{"key":"1094_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(02)09837-9","volume":"360","author":"SL Thomas","year":"2002","unstructured":"Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360:678\u201382.","journal-title":"Lancet"},{"key":"1094_CR24","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","volume":"20","author":"M Brisson","year":"2002","unstructured":"Brisson M, Gay NJ, Edmunds WJ, Andrews N. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500\u20137.","journal-title":"Vaccine"},{"key":"1094_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cid\/cir436","volume":"53","author":"J Gaillat","year":"2011","unstructured":"Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, et al. Does monastic life predispose to the risk of Saint Anthony\u2019s fire (herpes zoster)? Clin Infect Dis. 2011;53:405\u201310.","journal-title":"Clin Infect Dis"},{"key":"1094_CR26","doi-asserted-by":"crossref","unstructured":"Marangi L, Mirinaviciute G, Flem E, Scalia Tomba G, Guzzetta G, Freiesleben de Blasio B et al. The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster. PLoS ONE. 2017; 12: e0176845\u201317","DOI":"10.1371\/journal.pone.0176845"},{"key":"1094_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12889-015-1861-8","volume":"15","author":"O Damm","year":"2015","unstructured":"Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15:222.","journal-title":"BMC Public Health"},{"key":"1094_CR28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.ebiom.2015.08.017","volume":"2","author":"A van Lier","year":"2015","unstructured":"van Lier A, Lugn\u00e9r A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, et al. Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster. EBioMedicine. 2015;2:1494\u20139.","journal-title":"EBioMedicine"},{"key":"1094_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4161\/hv.23334","volume":"9","author":"J Bilcke","year":"2014","unstructured":"Bilcke J, van Hoek AJ, Beutels P. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Hum Vaccin Immunother. 2014;9:812\u201322.","journal-title":"Hum Vaccin Immunother."},{"key":"1094_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","volume":"20","author":"M Brisson","year":"2002","unstructured":"Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20:1113\u201325.","journal-title":"Vaccine"},{"key":"1094_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/adc.88.10.862","volume":"88","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88:862\u20139.","journal-title":"Arch Dis Child"},{"key":"1094_CR32","unstructured":"Human Mortality Database University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany) \n                    http:\/\/www.mortality.org\n                    \n                  . Accessed 3 May 2018."},{"key":"1094_CR33","unstructured":"Database of the Italian Institute of Statistics. Italian National Institute of Statistics (ISTAT), Rome, Italy. \n                    http:\/\/demo.istat.it\/\n                    \n                  . Accessed 3 May 2018."},{"key":"1094_CR34","doi-asserted-by":"publisher","first-page":"20132676","DOI":"10.1098\/rspb.2013.2676","volume":"281","author":"S Merler","year":"2014","unstructured":"Merler S, Ajelli M. Deciphering the relative weights of demographic transition and vaccination in the decrease of measles incidence in Italy. Proc R Soc B. 2014;281:20132676.","journal-title":"Proc R Soc B"},{"key":"1094_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1473-3099(17)30421-8","volume":"17","author":"F Trentini","year":"2017","unstructured":"Trentini F, Poletti P, Merler S, Melegaro A. Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis. Lancet Infect Dis. 2017;17:1089\u201397.","journal-title":"Lancet Infect Dis"},{"issue":"(Suppl 2)","key":"1094_CR36","first-page":"30","volume":"14","author":"RW Johnson","year":"2007","unstructured":"Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be managed? Herpes. 2007;14((Suppl 2)):30\u20134.","journal-title":"Herpes"},{"key":"1094_CR37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.292.6.704","volume":"292","author":"JF Seward","year":"2004","unstructured":"Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. J Am Med Assoc. 2004;292:704\u20138.","journal-title":"J Am Med Assoc"},{"key":"1094_CR38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","volume":"28","author":"R Civen","year":"2009","unstructured":"Civen R, Chaves SS, Jumaan AO, Wu H, Mascola L, Gargiullo PM, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28:954\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"1094_CR39","volume-title":"Piano Nazionale Prevenzione Vaccinale","author":"Ministero della Salute","year":"2017","unstructured":"Ministero della Salute. Piano Nazionale Prevenzione Vaccinale. Rome: Gazzetta Ufficiale; 2017."},{"key":"1094_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1056\/NEJM200103293441302","volume":"344","author":"M V\u00e1zquez","year":"2001","unstructured":"V\u00e1zquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955\u201360.","journal-title":"N Engl J Med"},{"key":"1094_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1017\/S0950268801005398","volume":"126","author":"G Gabutti","year":"2001","unstructured":"Gabutti G, Penna C, Rossi M, Salmaso S, Rota MC, Bella A, et al. The seroepidemiology of varicella in Italy. Epidemiol Infect. 2001;126:433\u201340.","journal-title":"Epidemiol Infect"},{"key":"1094_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF03320660","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics Ital Res Articles. 2009;11:83\u201393.","journal-title":"Pharmacoeconomics Ital Res Articles"},{"key":"1094_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19:929\u201335.","journal-title":"Value Health"},{"key":"1094_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/0962280211419832","volume":"24","author":"G Baio","year":"2011","unstructured":"Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Stat Methods Med Res. 2011;24:615\u201334.","journal-title":"Stat Methods Med Res"},{"key":"1094_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E","volume":"8","author":"AH Briggs","year":"1999","unstructured":"Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 1999;8:257\u201361.","journal-title":"Health Econ"},{"key":"1094_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Dec Making. 1998;18:202\u201312.","journal-title":"Med Dec Making"},{"key":"1094_CR47","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.clinthera.2015.01.006","volume":"37","author":"KJ Littlewood","year":"2015","unstructured":"Littlewood KJ, Ouwens MJNM, Sauboin C, Tehard B, Alain S, Denis F. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. Clin Ther. 2015;37:830\u20137.","journal-title":"Clin Ther"},{"key":"1094_CR48","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","volume":"30","author":"AJ van Hoek","year":"2012","unstructured":"van Hoek AJ, Melegaro A, Gay NJ, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30:1225\u201334.","journal-title":"Vaccine"},{"key":"1094_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0983-5","volume":"16","author":"J Horn","year":"2018","unstructured":"Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, et al. Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany \u2013 a mathematical modelling study. BMC Med. 2018;16:1\u20139.","journal-title":"BMC Med"},{"key":"1094_CR50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900\u20139.","journal-title":"Clin Infect Dis"},{"key":"1094_CR51","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"H-F Tseng","year":"2016","unstructured":"Tseng H-F, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged \u2265\u200960 years. J Infect Dis. 2016;213:1872\u20135.","journal-title":"J Infect Dis"},{"key":"1094_CR52","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, D\u00edez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396.","journal-title":"N Engl J Med"},{"key":"1094_CR53","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, D\u00edez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019\u201332.","journal-title":"N Engl J Med"},{"key":"1094_CR54","volume-title":"No excuses, people: get thenew shingles vaccine","author":"P Span","year":"2017","unstructured":"Span P. No excuses, people: get thenew shingles vaccine. New York City: The New York Times; 2017. \n                    https:\/\/nyti.ms\/2ho3vmE\n                    \n                  . Accessed 3 May 2018"},{"key":"1094_CR55","doi-asserted-by":"crossref","unstructured":"Marchetti S, Guzzetta G, Flem E, Mirinaviciute G, Scalia Tomba G, Manfredi P. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. Vaccine 2018; 36: 1116\u2013125.","DOI":"10.1016\/j.vaccine.2018.01.038"},{"key":"1094_CR56","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1099\/jmm.0.000061","volume":"64","author":"C Trucchi","year":"2015","unstructured":"Trucchi C, Gabutti G, Rota MC, Bella A. Burden of varicella in Italy, 2001\u20132010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. J Med Microbiol. 2015;64:1387\u201394.","journal-title":"J Med Microbiol"},{"key":"1094_CR57","first-page":"231","volume":"53","author":"C Signorelli","year":"2017","unstructured":"Signorelli C, Odone A, Cella P, Iannazzo S, D'Ancona F, Guerra R. Infant immunization coverage in Italy (2000-2015). Ann Ist Super Sanit\u00e0. 2017;53:231\u20137.","journal-title":"Ann Ist Super Sanit\u00e0"},{"key":"1094_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMp048320","volume":"352","author":"M V\u00e1zquez","year":"2005","unstructured":"V\u00e1zquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med. 2005;352:439\u201340.","journal-title":"N Engl J Med"},{"key":"1094_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","volume":"21","author":"N Thiry","year":"2003","unstructured":"Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes. PharmacoEconomics. 2003;21:13\u201338.","journal-title":"PharmacoEconomics"},{"key":"1094_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1524-4733.2005.04005.x","volume":"8","author":"L Coudeville","year":"2005","unstructured":"Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8:209\u201322.","journal-title":"Value Health"},{"key":"1094_CR61","first-page":"1","volume-title":"UK population norms for EQ-5D. Centre for Health Economics Discussion Paper Series. Report No. 172","author":"P Kind","year":"1999","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Centre for Health Economics Discussion Paper Series. Report No. 172. York: University of York; 1999. p. 1\u201398."},{"key":"1094_CR62","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0895-4356(98)00036-5","volume":"51","author":"MV Bala","year":"1998","unstructured":"Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol. 1998;51:667\u201376.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 2","key":"1094_CR63","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1086\/522150","volume":"197","author":"SS Chaves","year":"2008","unstructured":"Chaves SS, Zhang J, Civen R, Watson BM, Carbajal T, Perella D, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis. 2008;197(Suppl 2):S127\u201331.","journal-title":"J Infect Dis"},{"key":"1094_CR64","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00006454-199905000-00004","volume":"18","author":"P Fornaro","year":"1999","unstructured":"Fornaro P, Gandini F, Marin M, Pedrazzi C, Piccoli P, Tognetti D, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J. 1999;18:414\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"1094_CR65","first-page":"29","volume":"14","author":"CM Zotti","year":"2002","unstructured":"Zotti CM, Maggiorotto G, Migliardi A. I costi della varicella. Ann Ig. 2002;14:29\u201333.","journal-title":"Ann Ig"},{"key":"1094_CR66","first-page":"21","volume":"14","author":"C Giaquinto","year":"2002","unstructured":"Giaquinto C, Sturkenboom M, Mannino S, Arpinelli F, Nicolosi A, Cantarutti L. Epidemiologia ed esiti della varicella in Italia: risultati di uno studio prospettico sui bambini (0\u201314 anni) seguiti dai pediatri di libera scelta (Studio Pedianet). Ann Ig. 2002;14:21\u20137.","journal-title":"Ann Ig"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1094-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-018-1094-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1094-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T19:06:27Z","timestamp":1563303987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1094-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1186\/s12916-018-1094-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"12 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"PP has received personal fees from Merck & Co. Inc. for consultancy activity outside of the submitted work. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"117"}}